

Section 430(2B) Companies Act 2006 statements

Marc Dunoyer

Further to the announcement made by AstraZeneca PLC (the Company) on 4 June 2021, Marc Dunoyer stepped down as Chief Financial Officer and retired from the Company's Board effective 1 August 2021. Effective the same date as his retirement from AstraZeneca's Board, Mr. Dunoyer became Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca. He continues to report to Mr. Soriot and will remain a member of AstraZeneca's Senior Executive Team.

Mr. Dunoyer will remain an employee of AstraZeneca and therefore he will receive no payments for loss of office; his in-flight incentive awards will continue to run their course and he will not receive any payments in respect of his retirement from the Board.

His remuneration for qualifying services as an Executive Director during 2021 will be disclosed in the usual way in AstraZeneca's Annual Report and Form 20-F Information 2021.

Geneviève Berger

Geneviève Berger retired as a Non-Executive Director of AstraZeneca PLC (the Company) on 11 May 2021, at the conclusion of the Company's annual general meeting.

In accordance with section 430(2B) of the Companies Act 2006, the Company confirms that no remuneration payment will be made by the Company to Ms Berger after she ceased to be a Non-Executive Director of the Company, nor will any payment for loss of office be made.

Graham Chipchase

Graham Chipchase retired as a Non-Executive Director of AstraZeneca PLC (the Company) on 11 May 2021, at the conclusion of the Company's annual general meeting.

In accordance with section 430(2B) of the Companies Act 2006, the Company confirms that no remuneration payment will be made by the Company to Mr Chipchase after he ceased to be a Non-Executive Director of the Company, nor will any payment for loss of office be made.